These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 11242607)

  • 1. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
    Gavin LA; Barth J; Arnold D; Shaw R
    Endocr Pract; 2000; 6(4):305-10. PubMed ID: 11242607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
    Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
    Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
    Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?
    Kirk JK; Pearce KA; Michielutte R; Summerson JH
    J Fam Pract; 1999 Nov; 48(11):879-82. PubMed ID: 10907625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.
    Strowig SM; Avilés-Santa ML; Raskin P
    Diabetes Care; 2002 Oct; 25(10):1691-8. PubMed ID: 12351463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
    Horton ES; Whitehouse F; Ghazzi MN; Venable TC; Whitcomb RW
    Diabetes Care; 1998 Sep; 21(9):1462-9. PubMed ID: 9727892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
    Bloomgarden ZT
    Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
    Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
    Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
    [No Abstract]   [Full Text] [Related]  

  • 11. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
    Scheen AJ; Lefèbvre PJ
    Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
    Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
    Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients.
    Fonseca V; Foyt HL; Shen K; Whitcomb R
    Diabetes Care; 2000 Mar; 23(3):354-9. PubMed ID: 10868865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
    N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus.
    Bell DS; Ovalle F
    Endocr Pract; 2002; 8(4):271-5. PubMed ID: 12173913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.
    Garber AJ
    Diabetes Obes Metab; 2000 Jun; 2(3):139-47. PubMed ID: 11220549
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
    Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
    Diabetes Care; 1996 Feb; 19(2):151-6. PubMed ID: 8718436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
    Inzucchi SE
    JAMA; 2002 Jan; 287(3):360-72. PubMed ID: 11790216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Troglitazone].
    Yamanouchi T
    Nihon Rinsho; 2000 Feb; 58(2):389-94. PubMed ID: 10707563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.